Cytori Therapeutics Inc (NASDAQ:CYTX) announced the publication today of the results from the 12 month clinical follow up of patients enrolled in the Scleradec-I …
Cytori Therapeutics Inc (NASDAQ:CYTX) announced that Mr. John D.
Cytori Therapeutics Inc (NASDAQ:CYTX) announced that the first patient has been enrolled and treated in the ADRESU trial, a late phase, physician-initiated Japanese clinical …
Recently, various executives have taken part in insider trading activity for the stocks of Cytori Therapeutics Inc (NASDAQ:CYTX), Caladrius Biosciences Inc (NASDAQ:CLBS), FireEye Inc (NASDAQ:FEYE), and Gran Tierra Energy …
Recently, various executives have taken part in insider buying activity for the stocks of Cytori Therapeutics Inc (NASDAQ:CYTX), Celldex Therapeutics, Inc. (NASDAQ:CLDX), Nuance Communications Inc.
Cytori Therapeutics Inc (NASDAQ:CYTX) announced the launch of its U.S.
Cytori Therapeutics Inc (NASDAQ:CYTX) announced that it has recently been informed that a company-supported trial in Japan has received approval to begin enrollment from …
Cytori Therapeutics Inc (NASDAQ:CYTX) announced that Mr. Jeremy Hayden has been appointed as General Counsel and VP of Business Development.
Cytori Therapeutics Inc (NASDAQ:CYTX) announced that Kerastem Technologies, a wholly owned subsidiary of Bimini Technologies, received U.S.
Roth Capital analyst Joseph Pantginis offered commentary on Cytori Therapeutics Inc (NASDAQ:CYTX) after the company announced complete enrollment of its Phase II ACT-OA study which evaluates …